Fresenius Kabi to acquire Akorn and Merck KGaA biosimilars business

Germany-headquartered Fresenius Kabi has agreed to acquire Akorn (Nasdaq: AKRX), a USA-based manufacturer and marketer of prescription and over-the-counter pharmaceutical products, for around $4.3 billion, or $34.00 a share, plus the assumption of debt of about $450 million.

The transaction is expected to close by early 2018 and to be accretive in 2018 to Fresenius Group net income and earnings per share (EPS), excluding integration costs. The deal is expected to close by early 2018 a

John Ducker, president and chief executive of Fresenius Kabi USA, said: “Akorn brings to Fresenius Kabi specialized expertise in development, manufacturing and marketing of alternate dosage forms, as well as access to new customer segments like retail, ophthalmology and veterinary practices. Its pipeline is also impressive, with approximately 85 ANDAs filed and pending with the FDA and dozens more in development.”